Results 1 to 10 of about 124,359 (116)

Real-world patterns in lipid profile testing and lipid-lowering therapy in hospitalized patients: The Jurasz Lipid Study [PDF]

International Journal of Cardiology. Cardiovascular Risk and Prevention
Aims: The aim of the Jurasz Lipid Study was to provide real-world evidence on lipid profile testing, as well as the prevalence of lipid-lowering therapy (LLT) in consecutive patients hospitalized in a tertiary multi-specialist hospital in Poland. Methods
Małgorzata Ostrowska, Jakub Ratajczak, Marcin Ziółkowski, Piotr Adamski, Tomasz Fabiszak, Klaudyna Grzelakowska, Ewa Laskowska, Piotr Niezgoda, Karolina Obońska, Julia M. Umińska, Maciej Banach, Krzysztof Chlebus, Piotr Jankowski, Eliano P. Navarese, Łukasz Szarpak, Maciej Grymuza, Jacek Konarski, Małgorzata Topolska, Jacek Kubica   +18 more
doaj   +2 more sources

Editorial: New drugs in lipid lowering therapy [PDF]

Frontiers in Cardiovascular Medicine
Ibadete Bytyçi, Maciej Banach, Ivan Pećin   +2 more
doaj   +2 more sources

Targeted Strategy in Lipid-Lowering Therapy

Biomedicines, 2022
Dyslipidemia is characterized by a diminished lipid profile, including increased level of total cholesterol and low-density lipoprotein cholesterol (LDL-c) and reduced level of high-density lipoprotein cholesterol (HDL-c). Lipid-lowering agents represent
Ezgi Dayar, Olga Pechanova
doaj   +1 more source

Modern possibilities of intensive treatment of dyslipidemia and gaps in its control: literature review [PDF]

КардиоСоматика, 2023
The article discusses modern approaches to screening for dyslipidemia and its control, target levels of low-density lipoproteins (LDL), initiation of lipid-lowering therapy depending on the total risk on the Systematic Coronary Risk Evaluation (SCORE ...
Vera N. Larina, Milada G. Golovko, Vladimir G. Larin, Tatyana N. Mironovna, Denis A. Orlov   +4 more
doaj   +1 more source

Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression

Lipids in Health and Disease, 2020
Background Several studies have investigated the association between non-statin lipid-lowering therapy and regression of atherosclerosis. However, these studies were mostly small and their results were not always robust.
Walter Masson, Martin Lobo, Daniel Siniawski, Graciela Molinero, Gerardo Masson, Melina Huerín, Juan Patricio Nogueira   +6 more
doaj   +1 more source

Lipid-lowering drug adherence and combination therapy effects on gastrointestinal cancer in patients with dyslipidemia without diabetes: a retrospective cohort study in South Korea

BMC Cancer, 2022
Background In aging populations, the number of people with high cholesterol levels is increasing. Appropriate management of high cholesterol levels with drugs such as statins may prevent secondary diseases.
Kyu-Tae Han, Seungju Kim
doaj   +1 more source

Topical issues concerning modern lipid-lowering therapy

Consilium Medicum, 2022
Hypercholesterolemia (high levels of atherogenic lipoproteins) is the main modifiable cardiovascular risk factor in most of the populations, including the Russian population.
Andrey V. Susekov
doaj   +1 more source

Impact of polygenic risk communication: an observational mobile application-based coronary artery disease study

npj Digital Medicine, 2022
We developed a smartphone application, MyGeneRank, to conduct a prospective observational cohort study (NCT03277365) involving the automated generation, communication, and electronic capture of response to a polygenic risk score (PRS) for coronary artery
Evan D. Muse, Shang-Fu Chen, Shuchen Liu, Brianna Fernandez, Brian Schrader, Bhuvan Molparia, André Nicolás León, Raymond Lee, Neha Pubbi, Nolan Mejia, Christina Ren, Ahmed El-kalliny, Ernesto Prado Montes de Oca, Hector Aguilar, Arjun Ghoshal, Raquel Dias, Doug Evans, Kai-Yu Chen, Yunyue Zhang, Nathan E. Wineinger, Emily G. Spencer, Eric J. Topol, Ali Torkamani   +22 more
doaj   +1 more source

Comparative effectiveness of statin therapy in patients with hypertension of high and very high cardiovascular risk in actual clinical practice in Irkutsk

Кардиоваскулярная терапия и профилактика, 2021
Aim. To study lipid-lowering therapy in patients with high and very high risk of cardiovascular events (CVEs) at the outpatient and inpatient care stages in Irkutsk.Material and methods.
O. A. Ivanova, S. G. Kuklin, S. S. Sizova, T. A. Novoselova, L. R. Gaifullina   +4 more
doaj   +1 more source

Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy

Drugs in Context, 2017
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that is mainly expressed in the liver but can also be found in the intestine and kidneys.
Constantine E Kosmas, Eddy DeJesus, Rosmery Morcelo, Frank Garcia, Peter D Montan, Eliscer Guzman   +5 more
doaj   +1 more source